Enhancer of zeste homolog-2(EZH2) is a key epigenetic regulator that functions as oncogene and also known for inducing altered trimethylation of histone at lysine-27 (H3K27me3) mark in various tumors. However, H3K27me3 targets and their precise relationship with gene expression are largely unknown in astrocytic tumors. In this study, we checked EZH2 messenger RNA and protein expression in 90 astrocytic tumors of different grades using quantitative PCR and immunohistochemistry, respectively. Further, genome-wide ChIP-seq analysis for H3K27me3 modification was also performed on 11 glioblastomas (GBMs) and 2 diffuse astrocytoma (DA) samples. Our results showed EZH2 to be highly overexpressed in astrocytic tumors with a significant positive correlation with grade. Interestingly, ChIP-seq mapping revealed distinct differences in genes and pathways targeted by these H3K27me3 modifications between GBM versus DA. Neuroactive ligand receptor pathway was found most enriched in GBM (P = 9.4 × 10 −25 ), whereas DA were found to be enriched in metabolic pathways. Also, GBM showed a higher enrichment of H3K27me3 targets reported in embryonic stem cells and glioma stem cells as compared with DAs. Our results show majority of these H3K27me3 target genes were downregulated, not only due to H3K27me3 modification but also due to concomitant DNA methylation. Further, H3K27me3 modification-associated gene silencing was not restricted to promoter but also present in gene body and transcription start site regions. To the best of our knowledge, this is the first high-resolution genome-wide mapping of H3K27me3 modification in adult astrocytic primary tissue samples of human, highlighting the differences between grades. Interestingly, we identified SLC25A23 as important target of H3K27me3 modification, which was downregulated in GBM and its low expression was associated with poor prognosis in GBMs.
Introduction
Glioblastoma (GBM) is the most common malignant primary brain tumor in humans representing over 70% of all brain malignancies with a median survival time of ~14 months (1) . Besides known genetic alterations like mutations in isocitrate dehydrogenase 1 (IDH1), TP53 and telomerase reverse transcriptase (TERT), amplification of epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptor (PDGFR) and the sole epigenetic alteration, namely promoter hypermethylation of O-6-methylguanine-DNA methyltransferase, the overall outcome in the clinical setup for the patients still remains elusive and poor (2) . Elucidation of underlying mechanisms that potentiate the aggressive behavior of GBM is important for developing new prognostic markers and therapeutic strategies. Polycomb group of genes are epigenetic regulators that can function as transcriptional regulators of specific sets of genes through chromatin modification (3) . Enhancer of zeste homolog 2 (EZH2) is the catalytic subunit of the polycomb repressive complex 2 (PRC2), which mediates silencing of the target genes that are involved in fundamental cellular processes via trimethylation of histone H3 on lysine 27 (H3K27me3), via their catalytic SET domain activity (4) . It establishes a repressive chromatin structure that ultimately contributes to the regulation of development and lineage commitment of stem cells as well as tumor progression. Increased expression of EZH2 has recently been described in various hematological and solid malignancies including breast, prostate (5) , urinary bladder (6), leukemia (7) , gastric, lung and hepatocellular carcinoma (8) . In addition, overexpression of EZH2 has been found to be associated with aggressive behavior and poor clinical outcome in prostate (8, 9) , breast and urinary bladder carcinomas (4) . Knockdown of EZH2 in prostate cancer cells has been found to be associated with growth arrest and reduced metastatic potential in vivo (9, 10) .
H3K27me3 was initially reported to regulate homeotic (HOX) gene expression and in early steps of X chromosome inactivation (11) . Literature suggests involvement of H3K27me3 in various vital processes including transcription, replication, DNA repair and modulating wide range of cellular processes involved in deciding cell fate decisions (12, 13) . Recent studies have also highlighted the association of H3K27me3 modifications with a large number of human malignancies (8, 14) . Low H3K27me3 levels have been associated with poor outcome in breast, ovarian and pancreatic cancers (15) . On the other hand, high levels have been associated with poor outcome in hepatocellular carcinomas (16) and esophageal squamous cell carcinomas (17) . In one important study, Velichutina et al. (18) using ChIP-on chip technology(chromatin immunoprecipitation combined with DNA microarray) reported H3K27me3-mediated silencing of cell cycle-related tumor suppressor genes in diffuse large B-cell lymphoma. In another study, Ke et al. (19) using H3K27me3 ChIP-on chip and microarray gene expression data in prostate cancer cell lines (EP156T and PC3) highlighted its role in distinct biological functions (like multicellular organismal process, system development, cell-cell communication and signaling). Thus, it is apparent from the literature that H3K27me3 modifications control several cancer-related phenomena. Interestingly, new epigenetic regulators involved in maintenance of H3K27me3 mark-like demethylases JMJD3 and UTX (20) has been reported.
However, there are limited reports available for these genes in few tumors like urothelial (21), colon (22) and breast (23) and the detail mechanistic role and outcome of these enzymes (UTX/ KDM6A, JMJD3/KDM6B) are not explored in detail. Thus, these molecules were not considered for the analysis in the present study in correlation with H3K27me3.
In gliomas, few genome-wide binding profiles available for H3K27me3 have been generated in cell lines (24) (25) (26) . Although these studies provide information about global H3K27me3 map, they might not be optimal when investigating many important H3K27me3 modifications existing in human tumor samples (being restricted to cell line population only). Bender et al. (27) generated H3K27me3 map by utilizing four pediatric high-grade glioma tissues (two H3.3 mutants and two wild-types). However, as the authors focused only on H3K27me3 target genes in pediatric cases to discriminate variations in H3.3 K27 mutant tumors versus wild-type, this data cannot be applied to diverse group of adult glioma cases. Analyzing H3K27me3 target genes only in two cases may not represent the tumor heterogeneity observed in defining H3K27me3 modifications in GBM cases and other high-grade glioma populations. Thus, it is warranted to evaluate the global status of H3K27me3 target genes in high-grade gliomas (GBMs) and correlate these profile changes with respect to normal brain as well as low-grade gliomas [diffuse astrocytoma (DAs)] in adults.
Further, no study till date has analyzed H3K27me3 profile in primary human tumor samples of low-and high-grade gliomas, especially in relation to EZH2 expression. Hence, in the present study, we first evaluated EZH2 messenger RNA (mRNA) and protein expression in different grades of gliomas. Next, we analyzed and compared EZH2/polycomb complex-mediated H3K27me3 target genes in GBMs and DAs using ChIP followed by next-generation sequencing (ChIP-seq). Although this study specifically tries to identify distinct H3K27me3 modificationmediated epigenetic profile in low-and high-grade astrocytic tumors, it does not aim to distinguish between biologically various forms of GBM subtypes on the basis of molecular alterations (like IDH1, TP53, TERT mutation or EGFR/PDGFR amplification). Target genes so obtained in GBMs were further compared with H3K27me3 modification profile reported previously in non-neoplastic brain, embryonic stem cells (ESCs) and glioma stem cells (GSCs) profile. H3K27me3 target genes were also analyzed for expression stats using The Cancer Genome Atlas (TCGA) data as well as with reported DNA methylation profiles. In addition to neuroactive pathways, SLC25A23, a solute carrier molecule was identified as an important H3K27me3 target, whose low expression was associated with poor survival as compared with high expression, both in our cohort and in TCGA. To the best of our knowledge, this is the first comprehensive analysis focused to understand H3K27me3 modification status in adult GBM and DA tissue samples and also deliver a novel prognostic marker for GBMs regulated by H3K27me3.
Materials and methods
Astrocytic tumors (52 GBM, 24 AA and 14 DA) were selected for this study after ethical approval from Institute Ethical Committee. Age, sex and clinical history of all the patients were noted. Total RNA was isolated using mirVana™ miRNA isolation kit (Life Technologies, Carlsbad, CA; cat. no. AM1560), first-strand complementary DNA was synthesized by SuperScript® VILO™ complementary DNA synthesis kit (Life Technologies), and real-time PCR-based mRNA expression studies were performed using EZH2 and SLC25A23-specific primers (Supplementary 
Results and discussion

EZH2 mRNA and protein expression
In the present study, we first quantified the levels of EZH2 in DA, AA and GBM at transcript level using quantitative real-time PCR. The expression of EZH2 mRNA was found significantly higher in all grades of astrocytic tumors as compared with normal brain. Moreover, its expression showed a significant positive correlation with tumor grade, being significantly increased in high-grade tumors(grade IV > grade III > grade II; Figure 1a and b). Similar to the mRNA expression profile, immunopositivity for EZH2 protein was found not to be expressed in the normal brain, reactive glial tissue and the background non-neoplastic glia. However, immunopositivity for EZH2 protein was infrequent (with low labeling index) in DA tumors and became more frequent and widespread in higher grades (AA and GBM; 
Extracting ChIP-seq data and quality control
Because EZH2 is an important epigenetic regulator, we hypothesized that this high level of EZH2 may play a fundamental role in gliomagenesis by inducing epigenetic reprogramming of H3K27me3 modification marks. Hence, we performed ChIP to identify the genome-wide binding profile associated with these H3K27me3 modifications using primary tissue samples of both low-grade (DA) and high-grade (GBM) astrocytic tumors. Further, an initial quality control was performed to assess the target enrichment in H3K27me3 precipitated DNA in tissue samples using quantitative real-time PCR. The results showed an average enrichment of ~15-fold for positive target (HOXA9) as compared with negative target (GAPDH) in precipitated DNA ( Figure 1d ). ChIP-precipitated samples from the tissues were sequenced using HiSeq2000 platform, which generated an average of 21.51 million reads (range 12-28 million reads; Figure 1e and f). In addition to the present data, we also analyzed previously published ChIP-seq data sets for H3K27me3 profile for frontal and temporal lobes of non-neoplastic brain (29 Figure 1a and b, available at Carcinogenesis online). Our ChIP-quantitative PCR rate for the targets was good, indicating an efficient quality of the sequencing data.
Downstream pipeline for identification of preferential H3K27me3 gene targets
In order to keep data unambiguous, only top 1000 H3K27me3 peaks (on the basis of cutoff value ofP < 0.001) of each GBM and DA sample were selected for downstream analysis (suggested and modified method per Zhang et al. (34) . Detailed description of informatics pipeline is described in Supplementary Figure 2 , available at Carcinogenesis online. For GBM samples, all selected 1000 H3K27me3 peaks (n = 11) were combined and the removal of repetitive targets was done. This resulted in 7043 targets in coding region (gene coding) and 3957 targets of noncoding region (includes microRNA, ribosomal RNA, transfer RNA, Piwiinteracting RNA and small nucleolar RNA). As the main focus of this study was to analyze the effect of H3K27me3 modification on gene expression, only coding region in H3K27me3 targets were considered for analysis. Further, as suggested by Young et al. (35) , these 7043 H3K27me3 targets in coding region were classified into three distinct H3K27me3 'genomic enrichment sites', namely transcriptional start site (TSS), promoter (PMT) and gene body (GB). Repetitive targets in each enrichment region were next removed while keeping only one representative peak with most significant P value among replicates. This resulted in 4657 total unique targets of H3K27me3 modifications, of which GB region accounted for the largest with 59% (n = 2755), followed by PMT region with 23% (n = 1059) and TSS region with 18% (n = 843). For representing the most vital targets regulated by H3K27me3, a maximum of 1000 targets (with least P value) under each 'genomic enrichment sites' (i.e. GB, PMT and TSS regions) were finally selected. These criteria resulted in 1000 targets each for GB and PMT regions and 843 targets for TSS region (Supplementary Table 2 , available at Carcinogenesis online). For all downstream analysis, these selected targets are represented as 'target genes' under GBM profile (i.e. GB_GBM, PMT_GBM and TSS_GBM).
In the case of DA samples, a similar approach of peak sorting was performed, which resulted in 1383 targets in coding and 617 targets in noncoding regions. Removal of duplicates and classification of each coding targets into three 'genomic enrichment sites' resulted in 82% targets in GB region (n = 1085), 13% in PMT (n = 185) and 4% in TSS (n = 55) region. Similar to approach followed in GBM, a maximum of top 1000 targets under GB, PMT and TSS profiles were selected, which finally resulted in 1000 targets for GB, 185 for PMT and 55 for TSS regions (Supplementary  Table 2 , available at Carcinogenesis online). For all downstream analysis, these selected targets are denoted as 'target genes' under DA profile (i.e. GB_DA, PMT_DA and TSS_DA). In both GBM and DA samples, maximum 'target genes' for H3K27me3 were observed in GB region followed by PMT and TSS (GB > PMT > TSS). Although, top 1000 target genes in GB region are included for analysis, the complete GB targets for GBM and DA are also provided (Supplementary Table 3 , available at Carcinogenesis online).
Distribution of binding sites of the H3K27me3 target genes in GBM and DA
In order to find out whether the H3K27me3 target genes were modified at single or at multiple 'genomic enrichment sites', the targets of GB, PMT and TSS regions were compared in both GBMs and Das (Figure 2a) . In GBM cases, 95 H3K27me3 target genes were found to be shared by 3 genomic sites that included genes such as PAX5, WNT and HOX family members. Further, >200 H3K27me3 target genes were found to be shared between 2 genomic sites in GBM (PMT and TSS = 256; PMT and GB = 225; GB and TSS = 216). On the contrary, none of the H3K27me3 target genes of DAs were common to all the three genomic enrichment sites and nearly negligible(≤2) H3K27me3 target genes were shared between two genomic sites (PMT and TSS = 1; PMT and GB = 2; GB and TSS = 2). Therefore, in GBMs, a large set of H3K27me3 target genes were marked at multiple genomic sites unlike in low-grade DAs. Moreover, analyzing DNA methylation status of H3K27me3 targets in GBM using previous studies (36) showed that targets in TSS regions (either alone or in combination) were associated with high levels of DNA methylation [GB_TSS (17.3%) > PMT_TSS (16.7%) > TSS(12.2%) > GB_ PMT_TSS (10.5%) > GB (8.56%) > GB_PMT (8.4%) > PMT (6.6%) (Supplementary Table 4 ), available at Carcinogenesis online]. However, PMT region showed the low levels of DNA methylation (6.6%). Interestingly, the target genes harboring H3K27me3 modification at all the three regions (i.e. GB, PMT and TSS) were found to show a moderate level (10.5%) of DNA methylation levels. Thus, targets with H3K27me3 modification at TSS regions seems to be regulated by both H3K27me3 and DNA methylation, whereas targets in PMT regions are majorly regulated by the effect induced by H3K27me3 modification alone.
Comparison of H3K27me3 profile of GBM and DA versus normal brain
We next studied the differences observed in H3K27me3 methylation profile in GBMs with normal brain (29) . For GBMs, 91.3% (n = 2597/2843) target genes were uniquely expressed in comparison with normal brain (Supplementary Figure 3a, available at Carcinogenesis online). On the basis of 'genomic enrichment sites', 34% (n = 881/2597) target genes were found to be present in GB, 35% (n = 909/2597) in PMT and 31% (n = 807/2597) in TSS region (Supplementary Figure 3a, available at Carcinogenesis online). Thus, the proportions of overlapping targets among GBMs with respect to normal brain were <8.7% (n = 246/2843). Analysis of H3K27me3 target genes that were found specifically in GBMs included homeobox genes, LHX-4/-6, CDX2, POU4F1, neuronal differentiation target genes like NEUROD-1/ -2, NEUROG-1/-2/-3, brain-specific cadherin CDH22 and regulators of cancer-related genes like TGFB1, WNT9A, YAP1, VEGFA, HES7, BMP3 and SNAI3. In the case of DAs, >95% (n = 1172/1240) of targets were noticeably different in comparison with normal brain (Supplementary Figure 3b , available at Carcinogenesis online). Sorting the genes basis of 'genomic enrichment sites' revealed that, 93.7% of GB region targets (n = 937/1000), 97.8% of PMT region targets (n = 181/185) and 98.1% of TSS region target (n = 54/55), genes were different in comparison with normal brain (Supplementary Figure 3b , available at Carcinogenesis online). Further, 5% of DA target genes were shared with normal brain (n = 68/1240). Notably, H3K27me3 target genes specifically found in DA were found to be involved in metabolic pathways like UDP glucuronosyltransferase 1 family members (UGT1A10/-5/-6/-7/-8/-9), aldehyde dehydrogenase 3 family members (ALDH3A-1/-2), calcium signaling pathway members (CACNA1A/-B/-C and RYR1/-2), glutamate receptors like GRIA4, GRIK3/-4 and cancer-related molecules like AXIN2, COL4A, WNT9A and LAMA1/-2). Thus, it is apparent from the present data that in comparison with normal brain, a large shift in H3K27me3 modification is observed in gliomas, and these target genes may play an important role in gliomagenesis and progression.
Comparison of H3K27me3 target gene profile between GBM and DA
We next investigated whether a distinct set of H3K27me3 regulated genes can differentiate GBM versus DA. On comparison, a large proportion of H3K27me3 target genes in GBMs were found to be different from DA, i.e. 93.2% (n = 2651/2843; Figure 2b ). On site basis evaluation, 85.4% (n = 854/1000) of GB region target genes were found to be different in GBM in comparison with DA. Also, differences were noted in PMT (96.1% [n = 961/1000]) and TSS genomic site (99.1% [n = 836/843]). Notably, only 6.8% (n = 192/2843) of GBM target genes were found to be shared with DA cases. This suggests significant differences in the H3K27me3 modification profile in low-grade (DA) when compared with high-grade (GBM) astrocytic tumors.
Comparison of H3K27me3 profile of GBM and DA with ESCs, fNSCs and GSCs H3K27me3 profile
High-grade tumors are reported to be associated with more malignant characteristics and higher percentage of stem celllike characters as compared with low grades. Because EZH2-mediated H3K27me3 modification has been reported to be associated with such properties, thus, in order to draw a relationship between H3K27me3 map of GBMs and DAs with ESCs, the present data were compared with a set of published human embryonic data of Guenther et al. (30) , which has a comprehensive analysis of H3K27me3 profile for six ESCs (human ESCs). Approximately 50% (n = 1405/2843) of GBM H3K27me3 target genes falling in each genomic site were found to be shared with H3K27me3 profile of ESCs (Supplementary Figure 4a , available at Carcinogenesis online). This is in agreement with the observation by Lin et al. (26) , where a comparison showed ~47.5% of target genes to be shared between them. On the contrary, only 21% (n = 258/1240) of DA gene targets were shared with ESC data (Supplementary Figure 4b , available at Carcinogenesis online). Thus, GBMs share a higher percentage of H3K27me3 modified target gene profile similar to ESCs in comparison with DA, and majority of these targets are linked with maintenance of stem cell-like state in GBMs.
Recent reports have suggested that H3K27me3 modifications are critical in conversion of gliogenic transition during brain development from neural stem cells (37) , and this could serve as a cell of origin for brain tumor stem cells (38, 39) . We compared H3K27me3 ChIP-seq data for fNSCs (25) with the present data and found ~35% (n = 1459/2242) of GBM genes and 17.4% (n = 1019/1235) of DA genes to be shared with fNSCs-H3K27me3 data (Supplementary Figure 4c and d, available at Carcinogenesis online). Thus, our results demonstrate that a higher percentage of fNSCs-H3K27me3 target genes are exhibited in GBMs as compared with DAs, indicating the presence of fetal stem cell-like state to be present in GBMs.
Further, GBM is also known to have a small population of self-renewing, tumorigenic cancer stem cells called as GSCs that contribute to tumor initiation and therapeutic resistance (40) . We hypothesized that GSCs when compared with ESCs utilize comparatively more repressive regions via epigenetic control mechanism. We compared the present H3K27me3 profile data of GBM and DA with H3K27me3 profile published on eight GSCs cell line by Lin et al. (26) . In comparison with GBM data, an average of 53.8% (n = 1527/2843) of H3K27me3 target genes was found to be shared with GSCs (Supplementary Figure 4e, available at Carcinogenesis online). For DA cases, an average of 34.2% (n = 423/1240) of target genes were found to be shared with GSCs H3K27me3 data (Supplementary Figure 4f, available at Carcinogenesis online). These observations suggest that H3K27me3-modified profile of stem cells are more enriched in GBMs when compared with DAs, indicating GBMs to have more stem cell-like state than DAs. Hence, these genes may have a vital role in influencing higher proliferation and may define aggressive behavior and therapeutic resistance associated with high-grade gliomas as compared with low grades.
Correlation of H3K27me3 target gene profile in GBMs with gene expression and methylation data from TCGA
H3K27me3 modifications are traditionally known to be a repressive mark and are generally associated with silenced promoters. Thus, the relationship between gene expression and H3K27me3 modifications was also evaluated in this study using expression data of GBMs from TCGA keeping ≤2-fold as cutoff for upregulated and downregulated expression. The analysis showed around 23.2% (n = 522/2247) H3K27me3 target genes were downregulated and only 9.2% (n = 207/2247) were upregulated, rest 67.5% (n = 1518/2247) remained unchanged in terms of expression (Figure 3a and b) . KEGG analysis of the target genes that were upregulated were noted in metabolic regulation (CYP27B1, PRIM2 and SHMT2), pathways in cancers (EGFR, FZD2, CDKN1A, MMP2 and FOS), Antigen-processing and -presentation (B2M, CIITA) and glioma-specific (CDK4, CDK6) genes.
DNA methylation represents another most widely studied epigenetic mark in gliomas that occurs at cytosine residues in the context of CpG dinucleotides. Although DNA and histone methylation are different sets of epigenetic modifications, they may be dependent on each other to determine the final gene expression profile. Further, cross-talk between these modifications may play an important role in the establishment of chromatin diversity within the genome. However, because DNA methylation is also known to play a vital role in repression of gene expression, we took another step to analyze whether the negative regulation of genes was independently regulated by H3K27me3 alone or was a combined effect of H3K27me3 as well as DNA promoter hypermethylation. To test this, we analyzed the downregulated target genes for their DNA methylation status using available data from Gene Expression Omnibus database (36) . It was interesting to note that of the 408 downregulated target genes with methylation data available, majority 74.02% (n = 302/408) showed both DNA hypermethylation and H3K27me3 silencing marks, whereas only 25.98% (n = 106/408) were observed to have H3K27me3 silencing mark alone (Figure 3c) . Thus, this highlights that majority of the H3K27me3 targets were downregulated by a combinatorial effect of H3K27me3 modifications as well as DNA methylation.
Neuroactive ligand-receptor pathway is enriched in GBMs
In order to identify H3K27me3-regulated pathways specific to GBM and DA groups, the H3K27me3 target gene reported in all the three genomic enrichment profile (GB, PMT and TSS) were combined for GBM and DA and multiple copy of repetitive targets as well as those shared with normal brain were removed. This resulted in 2241 H3K27me3 target genes for GBM and 1235 for DA. By comparing these targets, we observed 86.65% (1942/2241) H3K27me3 target genes to be exclusive to GBM and 75.79% (936/1235) gene targets to DA. KEGG pathway enrichment analysis was done using KEGG for these H3K27me3 gene targets specific to GBM and DA, respectively. In GBM, the most enriched pathway was neuroactive ligand-receptor pathway (P = 9.4 × 10 −25 ) that was enriched with 73 genes (Figure 4a) . The other top pathways were pathways in cancer (P = 3.4 × 10 ). In DA, we observed 37 pathways to be enriched with significant P values (Figure 4a) . The top pathways included were ascorbate and aldarate metabolism (P = 3.07 × 10 ) and so on. Neuroactive ligand-receptor signaling (KEGG: hsa04080) was the most prominent pathway found altered in GBMs. We analyzed the TCGA database for gene expression status of the 73 H3K27me3 target genes of this pathway, of which 27 genes showed significantly 2-fold changes (P < 0.05) in expression (Supplementary Table 5 , available at Carcinogenesis online). Interestingly, all of these 27 genes were found to be downregulated (Figure 4b and c) . We further speculated the involvement of DNA methylation in negative regulation of these genes. The DNA methylation status showed 74% (20/27) genes to be having significant DNA hypermethylation at these H3K27me3-modified genomic sites, thus suggesting a combinatorial silencing is mediated by both these epigenetic modifications. Interestingly, among these low expression of CHRNA3 and ADRA2A were found to be associated with the worst outcome in GBMs (Supplementary Figure 5 , available at Carcinogenesis online).
SLC25A23: H3K27me3 target gene with a prognostic role
Previous studies based on whole genome mapping of chromatin modifications in ESCs have shown the presence of distinct histone marks (i.e. H3K4me3 and H3K27me3) at certain genomic sites that are associated with active and repressed PMTs, respectively. Because PMT-mediated regulation of gene expression is a well-known phenomenon and the role of repressive histone marks at PMT region is a parallel reported event, we considered to analyze H3K27me3-downregulated targets from PMT region for further analysis. One such interesting gene was found belonging to the solute carrier family namely SLC25A23 that represents part of drug transport families. SLC molecules have recently gained therapeutic importance as an oncogene as well as tumor suppressor genes (26, (41) (42) (43) . SLC25A23 is a calcium-dependent mitochondrial solute carrier, which is known to transport metabolites, nucleotides and cofactors through the mitochondrial inner membrane.
Literature suggests that deregulation of solute carrier proteins may lead to accumulation of certain molecules within the cell (or organelles) and thus may become lethal if the accumulation reaches toxic levels (26) . Defects in many of the solute carrier genes are implicated in human diseases. Loss of SLC members in prostate and pancreatic cancers (41) and in gastric cancers (42) has been reported due to PMT hypermethylation. Recently, the role of SLC family members has also been reported in gliomas. Lin et al. (26) reported the existence of bivalent histone modifications on SLC17A7, which leads to the loss of its expression in GBMs. Using ChIP-seq and cell culture studies in T98 and U87 cell lines, an overexpression of SLC17A7 gene led to decreased cell proliferation, migration and invasion. This suggested active role of SLCs in maintaining tumor suppressor activity, which has been less explored thus far. Hence, in the present study, we analyzed the role of H3K27me3 target gene SLC25A23 molecule in our inhouse GBM cases as well as in TCGA cohort.
Gene expression analysis of SLC25A23 was performed in a cohort of 40 GBM samples and 6 controls, which showed significantly downregulation of SLC25A23 in GBMs as compared with the controls (P < 0.001; Figure 5a ). Of these 40 GBM cases, survival data for 28 cases (70%) were available. Kaplan Meir graph was plotted to correlate SLC25A23 mRNA expression with the patient outcome. The expression data were analyzed by keeping the median as cutoff (values above median was considered to be high expression and expression below median value was considered as low expression). The analysis showed that low SLC25A23 expression was associated with poorer outcome (P < 0.001; Figure 5b ). The median time of progression free survival for patients with low SLC25A23 was 31.8 weeks in contrast to those with high SLC25A23 which was 86.2 weeks. For validation of our in-house results, the expression of SLC25A23 was seen in large TCGA database and was also correlated with survival. Similar to our results, we observed downregulation of SLC25A23 in all cases of GBM (P < 0.0001; Figure 5c ) and a similar trend to poor prognosis was also noted in TCGA database (P = 0.031; Figure 5d ). This indicated that SLC25A23 may act as a novel prognostic marker for GBMs.
In order to confirm whether H3K27me3 plays a role in the regulation of SLC25A23, EZH2 knockdown (catalytic unit of polycomb repressive complex 2 complex which functions to induce H3K27me3) was perfomed in U87MG cell line and its effect on expression of SLC25A23 was analyzed. Interestingly, knockdown of EZH2 resulted in an increased SLC25A23 expression (by atleast 4-fold), confirming a direct role of H3K27me3 modification in epigenetically silencing the SLC25A23 gene expression (Figure 5e and f) . Previous studies have reported an active role of SLC25A23 in calcium ion uptake regulation with significant reactive oxygen species and cell death implications (44) . Further, in cancers, downregulation of calcium ion homeostasis proteins have been reported to develop chemoresistance (45) . Therefore, targeting these calcium ion transporters in order to enhance the proapoptotic potential of malignant cells may be a useful strategy in the treatment of gliomas. Thus, the present study highlights SLC25A23 as a potential new prognostic biomarker for GBMs and further studies are needed to establish its role.
Conclusion
This is possibly the first high-resolution genome-wide map of H3K27me3 modification in primary adult tissue samples using human gliomas. EZH2, which is overexpressed in all grades of gliomas, catalyzes the H3K27me3 and therefore the high levels of EZH2 may be playing a fundamental role in gliomagenesis and progression by inducing epigenetic reprogramming of these H3K27me3 marks. In majority, H3K27me3 modification contributes to silencing/repression of the target genes. The present study highlights that majority (70%) of H3K27me3 target genes are downregulated not only due to H3K27me3 modification but also due to concomitant with DNA hypermethylation. We identify three enrichment profiles in the genome-wide maps of H3K27me3 in gliomas, which also correlate with transcriptional activity. Thus, H3K27me3 modification in gliomas associated with gene silencing/repression is not restricted to PMT region but also present in GB and TSS regions. This suggests the importance of considering the precise enrichment region of H3K27me3 for regulation of gene expression. The present study also reports significant differences noted in the H3K27me3 profile between GBMs and Das: (i) Significantly more H3K27me3 targets are found in the coding region of GBMs (n = 7043) versus Das (n = 1383). (ii) differences are observed between GBM versus DA in the percentage of targets in each genomic enrichment region (GB = 59% GBM versus 82% DA; PMT = 23% GBM versus 13% DA; TSS = 18% GBM versus 4% DA). (iii) H3K27me3 targets are often shared between two to three genomic enrichment sites in GBMs. In contrast, there was negligible sharing in DAs. (iv) Both ESCand GSC-specific H3K27me3 target genes are more enriched in GBMs (50% and 54%, respectively) as compared with Das (21% and 34%, respectively). Interestingly, the shared genes between GBM and ESCs include stem cell maintenance regulators and differentiation markers. Abundance of such shared targets in GBMs may suggest them for contributing to more stemness characteristics/s phenotypes as well as therapeutic resistance in GBMs. (v) More than 90% of the target genes are noted to be different between GBM and DA. From this it can be suggested that different pathways are targeted in low-grade versus high-grade gliomas. Indeed, pathway differences are found on KEGG analysis of H3K27me3 target genes between GBM and DA. GBMs are found enriched in neuroactive ligandreceptor pathways, whereas DA shows enrichment of metabolic pathways. For the first time, we show the downregulation of neuroactive ligand-receptor pathway in GBMs, which is possibly attributable to H3K27me3 modification. The role of this pathway in gliomagenesis needs further study. Further, SLC25A23 appears to be a potential new prognostic biomarker for GBMs. This is a calcium-dependent mitochondrial solute carrier gene that appears to be downregulated by EZH2-mediated H3K27me3 silencing. Further studies are needed to establish its role as a new biomarker. Thus, this study not only provides an improved understanding of the epigenetic alterations associated with gliomagenesis and progression but also offers a novel view of complexity of regulation of gene expression in gliomas.
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